Jefferies London Healthcare Conference on November 18 – 19, 2021
2021 Phage Futures Congress Europe on November 23 – 24, 2021
NESS ZIONA, Israel, Nov. 17, 2021 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced upcoming presentations at the Jefferies London Healthcare Conference on November 18-19 and the 2021 Phage Futures Congress Europe on November 23-24.
|Jefferies London Healthcare Conference – November 18-19, 2021|
|Date & Time:||On-demand session will be available to conference attendees beginning
Thursday, November 18, 3:00 AM EST through November 19, 12:00 PM EST
|2021 Phage Futures Congress Europe – November 23-24, 2021|
|Presentation Title:||“Nebulized Bacteriophage Therapy for Chromic Pseudomonas aeruginosa
Pulmonary Infections in CF Patients”
|Date & Time:||November 23, 11:30 AM CET, 5:30 AM EST|
|Presenter:||Myriam Golembo, Ph.D.|
Live webcasts of the Jefferies London Healthcare Conference will be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.
About BiomX Inc.
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com
LifeSci Advisors, LLC